SecBot SecBot
SECBOTREPLAY Home › Report › HCM

HCM · HUTCHMED announced that regulatory filings for ORPATHYS (savolitinib)…

HUTCHMED (China) Ltd · 6-K filed Nov 2, 2026 at 06:06 ET

At the news

BULLISHIMPACT 6/10

6-K filed Nov 2, 2026 at 06:06 ET

HUTCHMED announced that regulatory filings for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in MET-driven EGFR-mutated lung cancer have been accepted for review by the EMA in Europe and the MHLW in Japan, following a US FDA NDA submission in September 2026. The filings are supported by positive SAFFRON Phase III data showing statistically significant improvements in progression-free survival and overall survival versus chemotherapy. This expands the global regulatory pathway for the combination, which is already approved in China and temporarily authorized in Switzerland.

  • EMA validated and accepted MAA for ORPATHYS plus TAGRISSO in Europe for MET-overexpressed/amplified NSCLC after EGFR-TKI progression.
  • Japan MHLW accepted NDA for same combination in unresectable, advanced or recurrent NSCLC with MET overexpression/amplification after EGFR-TKI therapy.
  • US FDA NDA for the combination was submitted in September 2026.
  • SAFFRON Phase III trial showed PFS HR 0.55 (p<0.001), median PFS 7.6 vs 5.4 months; OS HR 0.68 (p=0.010), median OS 17.8 vs 12.9 months.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access